reports
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 16, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 16, 2024, from Atlas Special Opportunities, LLC indicating that as of May 13, 2024, it held 1,000,850,000 shares of the th...
Deceuninck NV: 1 director
A director at Deceuninck NV sold 500,000 shares at 2.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Information on the Total Number of Voting Rights (Denominator) followi...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, ...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 13, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 9, 2024, from Atlas Special Opportunities, LLC indicating that as of May 2, 2024, it held 1,467,712,295 shares of the then outstan...
Important Advances in Oxurion's R&D Program on Geographic Atrophy seco...
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD ` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have the potent...
- Vincent Koppmair
Shurgard - Q1 2024 - A start to 2024
All store revenue up 7.1% YoY at EUR 93.4m driven by higher rent prices (4.2%), and larger portfolio (+4.9%), offset by lower occupancy (86.7%)Same store revenue up 4.0% (CER), average occupancy is down 60bps at 89.2% YoY, and in place rent up 3.3%.EPRA results up 12.6% YoY, EPRA EPS at EUR 0.35 (+3.1%) post ABB.Leverage remains very low at 14.6% (vs. 13% at December end) and net debt/EBITDA at 3.5x and ICR stands at 13.4x.We reiterate our ‘Buy' rating and EUR 47.00 TP.More details in our N...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,755,774 shares of the then o...
- Vincent Koppmair
Home Invest Belgium NV: 1 director
A director at Home Invest Belgium NV bought 1,025,850 shares at 13.080EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Publication Annual Report – Annual Shareholders' Meeting
Publication Annual Report – Annual Shareholders' Meeting Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. On this day as well, the Company has convened its Annual Shareholders' Meeting. The relevant documents pertaining to...
Oxurion Receives Transparency Notifications from Atlas Special Opportu...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Leuven, BELGIUM – April 11, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received two transparency notifications as follows: Oxurion received a first transparency notification on April 10, 2024, from Atlas Special Opportunities, LLC indicating that as of April 1, 2024, it held 1,6...
- Vincent Koppmair
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Pro...
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 450,000 in the framework of the Atlas Funding Program. On April 10, 2024, the Company issued the Eleventh Tranche consisting of 18 convertible bonds, for an aggrega...
Postponement Annual Shareholders Meeting - Amendment financial calenda...
Postponement Annual Shareholders Meeting - Amendment financial calendar Postponement Annual Shareholders Meeting - Amendment financial calendarLeuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding its financial calendar. Due to administrative reasons, the annual accounts of the Company have not been finalized yet. Hence, the Company has decided to postpone its Annual Shareholders Meeting to Thursday May 16, 2024. The on the Company website has been updated...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 28, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 27, 2024, from Atlas Special Opportunities, LLC indicating that as of March 19, 2024, it held 0 (zero) share...
Information on the Total Number of Voting Rights (Denominator) followi...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market oppo...
Information on the Total Number of Voting Rights (Denominator) followi...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven...
- Kristof Samoy
- Thomas Vranken
- Wim Lewi
OXURION announces its presence at the Paris SmallCap event on March 28...
OXURION announces its presence at the Paris SmallCap event on March 28, 2024. OXURION announces its presence at the Paris SmallCapevent on March 28, 2024. Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV (Euronext Brussels : OXUR), a Leuven-based biopharmaceutical company, is pleased to announce its participation in the SmallCap event, scheduled for March 28 in Paris. The event, organized in key cities such as Paris, London, Frankfurt and Amsterdam, serves as a platform for bringing together European issuers and a wider network of institutional investors and family offices across E...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 22, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 20, 2024, from Atlas Special Opportunities, LLC indicating that as of March 14, 2024, it held 269,785,563 sh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.